Axitinib (AG-013736) is an FDA approved, orally administered potent small molecule tyrosine kinase inhibitor (TKI), which inhibits VEGF receptor (VEGFR) 1-3, platelet-derived growth factor receptor beta (PDGFR-β) and receptor tyrosine kinase c-KIT (CD117) [115], and shows promising anti-vascular and anti-tumor activity in a variety of advanced stage cancers, including GBM [116,117,118]. This evidence concerns the gene PDGFRB and neoplasm.